Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,364.00
Bid: 12,398.00
Ask: 12,400.00
Change: 268.00 (2.22%)
Spread: 2.00 (0.016%)
Open: 12,150.00
High: 12,440.00
Low: 12,134.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-U.S. to send 4 mln doses of AstraZeneca vaccine to Mexico, Canada in loan deal -official

Thu, 18th Mar 2021 16:59

(Adds Psaki comment)

By Jeff Mason

WASHINGTON, March 18 (Reuters) - The United States plans to
send roughly 4 million doses of AstraZeneca's COVID-19 vaccine
that it is not using to Mexico and Canada in loan deals with the
two countries, an administration official told Reuters on
Thursday.

Mexico will receive 2.5 million doses of the vaccine and
Canada is to receive 1.5 million doses, the official said.

"We're lending a portion of our releasable doses of
AstraZeneca vaccine," the official said on condition of
anonymity. "We only put the virus behind us if we're helping our
global partners."

White House spokeswoman Jen Psaki confirmed the plan, first
reported by Reuters, to send doses to Mexico and Canada. "It is
not fully finalized yet but it is our aim," she told a daily
briefing.

The Biden administration has come under pressure from allies
worldwide to share vaccines, particularly from AstraZeneca,
which is authorized for use in other countries but not yet in
the United States.

AstraZeneca has millions of doses made in a U.S.
facility, and has said that it would have 30 million shots ready
at the beginning of April. The company's shares rose slightly on
the news.

The deal to share the vaccine, which is still being
finalized, does not affect President Joe Biden's plans to have
vaccine available for all adults in the United States by the end
of May, the official said. It does not reduce the supply of
available vaccine in the United States.

The deal is likely to be announced publicly in the coming
days.

Two officials said the vaccine would be delivered in "short
order" once the deal was completed, but they declined to give a
more specific timetable.

The "releasable" vaccines are ready to be used once they
arrive. Under the deal, the United States will share doses with
Mexico and Canada now with the understanding that they will pay
the United States back with doses in return. The official said
that would take place later this year.

The United States had no plans to share the vaccine with
other countries at this time, he said.

"They are our neighbors, they are our partners," the
official said about Mexico and Canada. Mexican President Andres
Manuel Lopez Obrador had requested the vaccine previously. The
official said the countries were in touch about the vaccine
loan. "We've been working through the diplomatic channels," he
said.

Reports of blood disorders have prompted more than a dozen
nations to suspend use of AstraZeneca's vaccine but on Thursday
the EU's drug watchdog said that after an investigation it is
still convinced the benefits of that vaccine outweigh the risks.

Biden has said if the United States has a surplus of
vaccine, it will share it with the rest of the world. The White
House has focused on vaccinating people in the United States,
which has seen more than 530,000 people die from virus.

The country was getting prepared to roll out the AstraZeneca
vaccine domestically if it gets authorization from the U.S. Food
and Drug Administration, the official said.

The official noted that the United States has pledged $4
billion to the COVAX vaccine facility that aims to deliver
coronavirus vaccines to poor countries.

The United States does not need the AstraZeneca shots to
meet its target of having enough doses for all U.S. adults by
the end of May.

The three authorized vaccine makers – Pfizer Inc/BioNTech
SE, Moderna Inc, and Johnson & Johnson – have promised to
deliver nearly 500 million doses to the United States by then.
(Reporting by Jeff Mason; additional reporting by Trevor
Hunnicutt and Caroline Humer; Editing by Heather Timmons and
Alistair Bell)

More News
Today 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
Today 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more
Today 17:04

LONDON MARKET CLOSE: London dips as eyes turn to UK inflation reading

(Alliance News) - Stock prices in London closed in the red on Tuesday, as investors nervously eye a key UK inflation reading, which could prompt the Bank of England to consider interest rate cuts.

Read more
Today 15:00

London close: Stocks fall ahead of key inflation reading

(Sharecast News) - London stocks ended in negative territory on Tuesday, influenced by the latest UK economic outlook from the International Monetary Fund (IMF) and comments from US Federal Reserve officials.

Read more
Today 12:03

CORRECT: Stocks fall but pound up as IMF ups UK forecast

(Correcting London Stock Exchange index prices.)

Read more
Today 12:00

LONDON MARKET MIDDAY: Stocks fall but pound up as IMF ups UK forecast

(Alliance News) - Stock prices in Europe were lower heading into Tuesday afternoon, with shares in New York also set for a muted open, as a recent rally for equities takes a pause.

Read more
Today 11:23

AstraZeneca aims for $80 bln in total revenue by 2030

Sees $80 bln in 2030 revenue by 2030

*

Read more
Today 09:04

LONDON MARKET OPEN: FTSE 100 declines after Asian stocks fall

(Alliance News) - Stock prices in London opened in the red on Tuesday, with some US interest rate cut optimism cooling after hawkish words from Federal Reserve central bankers.

Read more
Today 08:18

TOP NEWS: AstraZeneca eyes new era of growth with bold new revenue aim

(Alliance News) - AstraZeneca PLC on Tuesday set out its ambition to achieve USD80 billion in annual revenue by the end of the decade as it signalled a new "era of growth."

Read more
Today 07:52

LONDON BRIEFING: AstraZeneca plots "new era of growth"; SSP confident

(Alliance News) - London's FTSE 100 is called to open lower on Tuesday, following a mixed close in New York overnight, and tepid trade in Asia.

Read more
Today 07:34

AstraZeneca lays out plans to hit $80bn in revenues by 2030

(Sharecast News) - AstraZeneca has unveiled medium-term growth targets to nearly double group revenues by the end of the decade as it predicts significant growth from existing oncology, biopharmaceuticals and rare disease portfolios.

Read more
20 May 2024 11:55

LONDON MARKET MIDDAY: Gold shines amid interest rate cut hopes

(Alliance News) - Stock prices in London got a boost at midday on Monday, as investors eye a key UK inflation reading later in the week, which is expected to show cooling prices.

Read more
20 May 2024 08:56

AstraZeneca to build $1.5-bln cancer drug plant in Singapore

Plans to build ADCs manufacturing facility in Singapore

*

Read more
20 May 2024 08:24

TOP NEWS: AstraZeneca plans to build manufacturing plant in Singapore

(Alliance News) - AstraZeneca PLC on Monday announced plans for a USD1.5 billion manufacturing facility in Singapore to produce antibody drug conjugates, treatments that deliver "highly potent cancer-killing agents".

Read more
20 May 2024 07:47

LONDON BRIEFING: Keywords would back GBP2.0 billion bid as EQT circles

(Alliance News) - London's FTSE 100 is called to open higher at the start of the week, while the pound climbed and gold hit another record high, with investors hopeful the Federal Reserve could soon cut US interest rates.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.